Sheng Wanying, Ding Yan, Su Yuting, Hu Jing, Wang Lu, Guo Minjie, Yuan Xiao, Wang Deqiang, Dai Chunhua, Wang Xu
Department of Thoracic Oncology, Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Cancer Center, Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
BMC Immunol. 2025 May 24;26(1):41. doi: 10.1186/s12865-025-00722-7.
The identification of affordable and easily accessible indicators to predict overall survival is important for tumor immunotherapy. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which promote tumor immune escape in the tumor microenvironment (TME). This study aimed to determine whether peripheral blood MDSCs could determine their potential as predictors of survival in tumor patients with immunotherapy.
Flow cytometry was used to detect peripheral blood monocytic myeloid-derived suppressor cells (M-MDSCs) and granulocytic myeloid-derived suppressor cells (G-MDSCs) in 126 patients. Multivariate Cox regression analysis was conducted to examine the associations between peripheral blood MDSCs and patient survival. The receiver operating characteristic (ROC) curve determined the optimal cutoff value for peripheral blood MDSCs and grouped the indicators. The relationship between peripheral blood M-MDSCs and the prognosis and treatment outcome of tumor patients was explored.
The proportion of peripheral blood M-MDSCs was associated with the prognosis of patients with tumors, as were tumor metastasis, the red blood cell count, absolute neutrophil count, absolute monocyte count, and BMI. Multivariate Cox regression analysis revealed that M-MDSCs, absolute lymphocyte value, and tumor metastasis were independent risk factors affecting the prognosis of patients with tumors. Detection of peripheral blood M-MDSCs obtained high sensitivity and specificity for tumor diagnosis. Patients with high M-MDSCs percentage demonstrated reduced survival durations and diminished responses to immunotherapy compared to those with low M-MDSCs percentage.
Peripheral blood M-MDSCs may be used to predict overall survival and immunotherapy efficacy outcomes. This study provides a putative predictive biomarker for clinicians to choose from to predict tumor patients' survival and the selection of receiving immunotherapy regimens.
识别可负担且易于获取的预测总生存期的指标对肿瘤免疫治疗至关重要。髓系来源的抑制细胞（MDSCs）是一群异质性的未成熟髓系细胞，可在肿瘤微环境（TME）中促进肿瘤免疫逃逸。本研究旨在确定外周血MDSCs是否可作为肿瘤免疫治疗患者生存期的预测指标。
采用流式细胞术检测126例患者外周血中的单核细胞源性髓系抑制细胞（M-MDSCs）和粒细胞源性髓系抑制细胞（G-MDSCs）。进行多因素Cox回归分析以检验外周血MDSCs与患者生存期之间的关联。通过绘制受试者工作特征（ROC）曲线确定外周血MDSCs的最佳截断值并对指标进行分组。探讨外周血M-MDSCs与肿瘤患者预后及治疗效果之间的关系。
外周血M-MDSCs的比例与肿瘤患者的预后相关，肿瘤转移、红细胞计数、绝对中性粒细胞计数、绝对单核细胞计数和BMI也与之相关。多因素Cox回归分析显示，M-MDSCs、绝对淋巴细胞值和肿瘤转移是影响肿瘤患者预后的独立危险因素。外周血M-MDSCs检测对肿瘤诊断具有较高的敏感性和特异性。与M-MDSCs比例低的患者相比，M-MDSCs比例高的患者生存期缩短，对免疫治疗的反应减弱。
外周血M-MDSCs可用于预测总生存期和免疫治疗疗效。本研究为临床医生提供了一个可能的预测生物标志物，以便在预测肿瘤患者生存期和选择免疫治疗方案时进行参考。
